Aligos Therapeutics reported net income of -$1.50M for the quarter ended Jun 2026. This income statement covers 28 quarters of results from Sep 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | ||||||||||||||||||||||||||||
| Revenue | 1.54M | 0.37M | 2.57M | 3.69M | 4.11M | 3.54M | 2.58M | 4.29M | 2.15M | 2.01M | 0.69M | 1.06M | 1.25M | 0.61M | 0.31M | 0.96M | 0.74M | 0.17M | 2.83M | |||||||||
| Operating items | ||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 28.13M | 28.60M | 31.68M | 16.51M | 17.79M | 19.10M | 18.14M | 16.78M | 15.87M | 22.26M | 16.37M | 21.10M | 16.77M | 16.03M | 14.50M | 13.98M | 23.94M | 17.04M | 23.35M | 24.05M | ||||||||
| Selling, General & AdministrativeSG&A | 6.47M | 9.72M | 6.45M | 7.58M | 5.26M | 7.12M | 8.51M | 9.25M | 6.44M | 6.42M | 6.67M | 6.38M | 4.63M | 5.16M | 5.05M | 5.56M | 5.17M | 4.95M | 6.41M | 5.62M | ||||||||
| Other Operating ExpensesOther Opex | 0.07M | 0.18M | -0.01M | 0.52M | 0.28M | 0.84M | 1.00M | 1.11M | 1.06M | 0.24M | 1.58M | 1.23M | 1.07M | 0.57M | 0.88M | 1.21M | 1.08M | 0.75M | 0.81M | 0.22M | ||||||||
| Operating ExpensesOpex | 34.60M | 38.31M | 38.13M | 24.09M | 23.05M | 26.22M | 26.64M | 26.03M | 22.31M | 28.68M | 23.03M | 27.48M | 21.40M | 21.19M | 19.55M | 19.53M | 29.10M | 21.98M | 29.76M | 29.67M | ||||||||
| Operating IncomeOp. Inc | -33.07M | -37.95M | -35.56M | -20.39M | -18.95M | -22.68M | -23.92M | -19.14M | -19.07M | -26.00M | -22.05M | -26.41M | -20.13M | -20.56M | -19.24M | -18.57M | -28.36M | -21.81M | -26.93M | -1.89M | ||||||||
| EBIT | -33.07M | -37.95M | -35.56M | -20.39M | -18.95M | -22.68M | -23.92M | -19.14M | -19.07M | -26.00M | -22.05M | -26.41M | -20.13M | -20.56M | -19.24M | -18.57M | -28.36M | -21.81M | -26.93M | -1.89M | ||||||||
| Non-operating items | ||||||||||||||||||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.00M | -0.74M | ||||||||||||||||||||||||||
| Net income details | ||||||||||||||||||||||||||||
| EBT | -33.00M | -37.77M | -35.56M | -19.88M | -18.66M | -21.84M | -22.92M | -18.03M | -18.01M | -27.92M | -34.84M | 5.25M | -19.17M | -82.12M | 43.13M | -15.68M | -31.48M | -19.85M | -22.72M | 1.31M | ||||||||
| Tax ProvisionsTaxes | 0.13M | -0.06M | 0.05M | 0.05M | -0.04M | 0.05M | 0.04M | 0.76M | 0.03M | -0.03M | 0.02M | 0.19M | 0.09M | 0.03M | 0.04M | 0.18M | 0.06M | -5.30M | 0.32M | 2.81M | ||||||||
| Profit After TaxPAT | -33.12M | -37.65M | -35.86M | -20.08M | -18.62M | -21.64M | -22.95M | -18.79M | -18.04M | -27.89M | -34.86M | 5.06M | -19.26M | -82.24M | 43.09M | -15.89M | -31.54M | -19.88M | -23.04M | -1.50M | ||||||||
| Income from Continuing OperationsIncome (Continuing) | -33.12M | -37.71M | -35.62M | -19.92M | -18.62M | -21.89M | -22.95M | -18.79M | -18.04M | -27.89M | -34.86M | 5.06M | -19.26M | -82.15M | 43.09M | -15.86M | -31.54M | -14.55M | -23.04M | -1.50M | ||||||||
| Consolidated Net IncomeConsol Net Inc. | -33.12M | -37.71M | -35.62M | -19.92M | -18.62M | -21.89M | -22.95M | -18.79M | -18.04M | -27.89M | -34.86M | 5.06M | -19.26M | -82.15M | 43.09M | -15.86M | -31.54M | -14.55M | -23.04M | -1.50M | ||||||||
| Income towards Parent CompanyParent Net Inc | -33.12M | -37.71M | -35.62M | -19.92M | -18.62M | -21.89M | -22.95M | -18.79M | -18.04M | -27.89M | -34.86M | 5.06M | -19.26M | -82.15M | 43.09M | -15.86M | -31.54M | -14.55M | -23.04M | -1.50M | ||||||||
| Net Income towards Common StockholdersNet Income | -33.12M | -37.71M | -35.62M | -19.92M | -18.62M | -21.89M | -22.95M | -18.79M | -18.04M | -27.89M | -34.86M | 5.06M | -19.26M | -82.15M | 43.09M | -15.86M | -31.54M | -14.55M | -23.04M | -1.50M | ||||||||
| Additional items | ||||||||||||||||||||||||||||
| EPS (Basic) | -0.78 | -0.95 | -0.84 | -0.47 | -0.44 | -0.51 | -0.53 | -0.43 | -0.41 | -0.43 | -0.22 | 0.03 | -3.07 | -13.11 | 5.12 | -1.53 | -3.04 | -1.47 | -2.21 | -0.14 | ||||||||
| EPS (Diluted) | -0.78 | -0.89 | -0.84 | -0.47 | -0.44 | -0.51 | -0.53 | -0.43 | -0.41 | -0.43 | -0.22 | 0.03 | -3.07 | -13.11 | 4.95 | -1.53 | -3.04 | -1.47 | -2.21 | -0.14 | ||||||||
| Shares Outstanding | 42.40M | 39.86M | 42.51M | 42.67M | 42.76M | 42.70M | 42.91M | 43.22M | 43.50M | 64.26M | 156.15M | 156.44M | 6.27M | 6.26M | 8.41M | 10.35M | 10.37M | 9.88M | 10.40M | 10.43M | ||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 42.40M | 42.40M | 42.51M | 42.67M | 42.76M | 42.70M | 42.91M | 43.22M | 43.50M | 64.26M | 156.15M | 156.65M | 6.27M | 6.26M | 8.71M | 10.35M | 10.37M | 9.88M | 10.40M | 10.43M | ||||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 42.61M | 42.69M | 42.70M | 42.81M | 42.82M | 42.92M | 42.94M | 43.50M | 43.50M | 64.26M | 156.15M | 156.44M | 6.27M | 6.26M | 8.41M | 10.35M | 10.37M | 9.88M | 10.40M | 10.43M | ||||||||
| EBITDA | -33.07M | -37.95M | -35.56M | -20.39M | -18.95M | -22.68M | -23.92M | -19.14M | -19.07M | -26.00M | -22.05M | -26.41M | -20.13M | -20.56M | -19.24M | -18.57M | -28.36M | -21.81M | -26.93M | -1.89M | ||||||||
| Tax Rate | -0.38% | 0.15% | -0.15% | -0.24% | 0.23% | -0.22% | -0.17% | -4.20% | -0.16% | 0.11% | -0.07% | 3.60% | -0.47% | -0.03% | 0.10% | -1.18% | -0.18% | 26.69% | -1.40% | 215.07% |